Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis

EXCLI Journal

Volumn 12, Issue , 2013, Pages 605-615

  Mahmound Ahmed, Mohammed ^a   Abdel Salam, Omar M E ^a   Mohammed, Nadia A ^a   Fakhry Habib, Dawoud ^a   Ezeldin Gomaa, Hewida ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Chronic hepatitis C; Interferon; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLUTATHIONE; MALONALDEHYDE; NITRIC OXIDE; PEGINTERFERON ALPHA2A; REIFERON RETARD; RIBAVIRIN; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROTHROMBIN TIME; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

HEPATITIS C VIRUS;

EID: 84879831267     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Ames B, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-62.
2. Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Ann Hepatol 2008;7:114-9.
3. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null respond-ers. Hepatology 2012;55:742-8.
4. Davies KJ, Sevanian AS, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes: A new aspect of the antioxidant functions of uric acid. Biochem J 1986;235: 747-54.
5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastro-enterology 2010;138:513-21.
6. Diaz KM, Feairheller DL, Sturgeon KM, Williamson ST, Brown MD. Oxidative Stress Response to Short Duration Bout of Submaximal Aerobic Exercise in Healthy Young Adults. Int J Ex Sci 2011;4: 247-56.
7. Dieterich DT, Rizzetto M, Manns MP. Management of chronic hepatitis C patients who have relapsed or not responded to pe-gylated interferon alfa plus ribavirin. J Viral Hepat 2009;16:833-43.
8. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013;56:961-7.
9. El-Kannishy G, Arafa M, Abdelaal I, Elar-man M, El-Mahdy R. Persistent oxidative stress in patients with chronic active hepatitis-C infection after antiviral therapy failure. Saudi J Gastroenterol 2012;18:375-9.
10. Ellman GL. Tissue sulfhydryl groups. Arch Biochem 1959;82:70-7.
11. Esmat G, Abdel Fattah S. Evaluation of a novel pegylated interferon alpha-2a (Rei-feron Retard) in Egyptian patients with chronic hepatitis C-genotype 4. Dig Liv Dis Suppl 2009;3:17-9.
12. Farias MS, Budni P, Ribeiro CM, Parisotto EB, Santos CE, Dias JF et al. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Gastroenter-ol Hepatol 2012;35:386-94.
13. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50.
14. Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 1980;26:227-31.
15. Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L et al. Prediction of response to pe-gylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J 2012;9: 123.
16. Gutteridge J. Lipid peroxidation and antiox-idants as biomarkers of tissue damage. Clin Chem 1995;41:1819-28.
17. Halliwell B. Production of superoxide, hydrogen peroxide and hydroxyl radicals by phagocytic cells: a cause of chronic inflammatory disease? Cell Biol Int Rep 1982;6:529-42.
18. Halliwell B. Free radicals, protein and DNA: oxidative damage versus redox regulation. Biochem Soc Trans 1996;24:1023-27.
19. Halliwell B. The wanderings of a free radical. Free Radic Biol Med 2009;46:531-42.
20. Halliwell B, Gutteridge JMC. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984;219:1-14.
21. Hokari A, Zeniya M, Esumi H, Ishikawa T, Kurasima Y, Toda G. Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C. J Infect 2005;51:47-53.
22. Horta MF, Mendes BP, Roma EH, Noronha FS, Macêdo JP, Oliveira LS et al. Reactive oxygen species and nitric oxide in cutaneous leishmaniasis. J Parasitol Res 2012: 203818. doi: 10.1155/2012/203818.
23. Ibrahim M, Gomaa W, Ibrahim Y, El Hadad H, Shatat M, Aleem AA et al. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study. J Gastrointest Liver Dis 2010;19:387-92.
24. Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G et al. Pegylated ar-ginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol 2007;22:86-91.
25. Kannan S. Free radical theory of autoim-munity. Theor Biol Med Model 2006;3:22.
26. Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 2001;54:356-61.
27. Lake-Bakaar G, Sorbi D, Mazzoccoli V. Nitric oxide and chronic HCV and HIV infections. Dig Dis Sci 2001;46:1072-6.
28. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15.
29. Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012;66:342-55.
30. Martin-Sanz P, Hortelano S, Callejas NA, Goren N, Casado M, Zeini M et al. Nitric oxide in liver inflammation and regeneration. Metab Brain Dis 2002;17:325-34.
31. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J et al. IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361: 580-93.
32. McNaughton L, Puttagunta L, Martinez-Cuesta MA, Kneteman N, Mayers I, Moqbel R et al. Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acad Sci USA 2002;99: 17161-6.
33. Medina J, Moreno-Otero R. Pathophysio-logical basis for antioxidant therapy in chronic liver disease. Drugs 2005;65:2445-61.
34. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995;41:892-6.
35. Pár A, Roth E, Miseta A, Hegedüs G, Pár G, Hunyady B et al. Effects of supplementation with the antioxidant flavonoid, si-lymarin, in chronic hepatitis C patients treated with peginterferon + ribavirin. A placebo-controlled double blind study. Orv Hetil 2009;150:73-9.
36. Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders-facts and controversies. Biochem Med (Zagreb) 2012;22: 63-75.
37. Pata C, Yazar A, Altintas E, Polat G, Aydin O, Tiftik N et al. Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis. Hepatogastroenterology 2003;50:794-7.
38. Pellicano R, Puglisi G, Ciancio A, Balzola F, Saracco G, Ciccone G et al. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection? J Med Virol 2008;80:628-31.
39. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;34:757-66.
40. Petta S, Macaluso FS, Cammà C, Marco VD, Cabibi D, Craxì A. Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. Liver Int 2012;32:1443-50.
41. Quarato G, Scrima R, Agriesti F, Mo-radpour D, Capitanio N, Piccoli C. Targeting mitochondria in the infection strategy of the hepatitis C virus. Int J Biochem Cell Biol 2013;45:156-66.
42. Rockey DC, Shah V. Nitric oxide biology and the liver: report of an aasld research workshop. Hepatology 2004;39:250-7.
43. Ruiz-Larrea MB, Leal AM, Liza M, Lacort M, de Groot H. Antioxidant effects of es-tradiol and 2-hydroxyestradiol on iron induced lipid peroxidation of rat liver micro-somes. Steroids 1994;59:383-8.
44. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-63.
45. Sarela AI, Mihaimeed FM, Batten JJ, Davidson BR, Mathie RT. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 1999;44:749-53.
46. Sharma P, Jha AB, Dubey RS, Pessarakli M. Reactive oxygen species, oxidative damage, and antioxidative defense mechanism in plants under stressful conditions. J Botany 2012;2012:1-26.
47. Sherman KE, Fleischer R, Laessig K, Murray J, Tauber W, Birnkrant D. Development of novel agents for the treatment of chronic hepatitis C infection: summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology 2007;46: 2014-20.
48. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon al-pha-2a and -2b in combination with ribavi-rin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:3-4,1-125.
49. Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia A et al. Multispecific T cell response and negative HCV-RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004;53:1673-81.
50. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 1989;86:1398-400.
51. Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010;24:597-602.
52. Tsukiyama-Kohara K. Role of oxidative stress in hepatocarcinogenesis induced by hepatitis C virus. Int J Mol Sci 2012;13: 15271-8.
53. Wang W, Ballatori N. Endogenous gluta-thione conjugates: occurrence and biological functions. Pharmacol Rev 1998;50:335-56.
54. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 2009;49:665-75.
55. Yen HH, Shih KL, Lin TT, Su WW, Soon MS, Liu CS. Decreased mitochondrial de-oxyribonucleic acid and increased oxidative damage in chronic hepatitis C. World J Gas-troenterol 2012;18:5084-9.
56. Young IS. Measurement of total antioxidant capacity. J Clin Pathol 2001;54:339.